

96. Shearer RJ, Davies JH, Gelister JS, et al. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. *Br J Urol* 1992; 69: 521-4
97. Klarskov P, Lund F, Petersen SE. Secondary treatment of advanced cancer of the prostate with Zoladex. *Int Urol Nephrol* 1990; 22: 359-62
98. Kerle D, Williams G, Ware H, et al. Experience with an LHRH analogue in the management of relapsed progressive prostatic cancer. *Br J Urol* 1984; 56: 495-8
99. Bouffioux C. Total androgen blockade in advanced prostatic cancer. Critical review and personal experience. *Eur Urol* 1988; 15: 187-92
100. Kaisary AV, Ryan PG, Turkes A, et al. A comparison between surgical orchidectomy and LH-RH analogue ('Zoladex', ICI 118,630) in the treatment of advanced prostatic carcinoma – a multi-centre clinical study. *Prog Clin Biol Res* 1988; 260: 89-100
101. Soloway MS, Chodak G, Vogelzang NJ, et al. Zoladex versus orchidectomy in treatment of advanced prostate cancer: a randomized trial. *Urology* 1991; 37: 46-51
102. Turkes AO, Peeling WB, Griffiths K. Treatment of patients with advanced cancer of the prostate: phase III trial, zoladex against castration; a study of the British Prostate Group. *J Steroid Biochem* 1987; 27: 543-9
103. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. *JAMA* 1995; 273 (4): 289-94
104. Gonadotrophin releasing hormone analogues for advanced prostate cancer. *Drug Ther Bull* 1992; 30: 65-6
105. Nicol DL, Heathcote PS, Kateley GD, et al. Advanced prostate cancer. The role of high priced hormone therapy. *Med J Aust* 1993; 159: 16-9
106. Rutqvist LE, Wilking N. Analogues of LHRH versus orchidectomy: comparison of the economic costs for castration in advanced prostate cancer. *Br J Cancer* 1992; 65: 927-9

Correspondence : *Rex N. Brogden*, Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand.

Erratum

Vol. 6, No. 1, page 49: Part of column 5 in table IV under the entry for Coon & Willis^[125] has been mistranscribed. The full entry should read: 'Frequency of bleeding: 6.1% for patients <40 years; 6.4% for patients 40-49 years; 6.4% for patients 50-59 years; 8.7% for patients 60-69 years, and 10.9% for patients ≥70 years; $p = 0.005$. Relative risk of bleeding: 1.8 (95% CI, 1.3-2.6) for patients ≥70 years compared with patients <40 years'.

[*Beyth RJ, Landefeld CS. Anticoagulants in older patients: a safety perspective. Drugs & Aging* 1994; 6 (1): 45-54]